The company also retains B2i Digital to enhance engagement with its investor community
NEW YORK, NY and TEL AVIV, Israel, September 2, 2022 (GLOBE NEWSWIRE) — via New Media Wire — Todos Medical Co., Ltd. (OTCQB: TOMDF), an integrated medical diagnostics and related solutions company, today announced King Calxis an American influencer with over 7.4 million followers across all platforms (5.8 million online). tick tock,One million Instagram and 600,000 Youtube), Tollovid™, a subsidiary of our majority-owned 3CL Pharma Ltd. 3CL protease inhibitor Immune support nutritional supplement brand. In collaboration with Kingcarlx, the company #TolloUp marketing campaign. Kingcarlx is Trobid The brand focused on encouraging its followers to use supplements daily for added protection in the face of a world of pandemics.
“After seeing a recently published market research study on Tollovid, research gateI’m very excited to be able to help Todos Expand the Tollovid brand across my social media platforms and encourage my followers to #TolloUp before attending social gatherings that may expose them to potential infections. “We’ve been indoors for the past two years, so I can relate to the urge to socialize, reunite, and make new memories. I love spending time with friends and family, but I always Safety comes first and we try to #TolloUp before every gathering.Tollovid provides an extra layer to keep us safe and give us more confidence and protection. “
Instagram: King Karlux
TikTok: King Karlux
Facebook: King Calx
Coinciding with this announcement, Todos also announced that it is holding a digital IR marketing company. B2i digital To help us reach investors online as we seek to grow our shareholder base long covid market opportunity.
David Shapiro, President and CEO of B2i Digital, Inc. and Chief Marketing Officer of the National Investment Bankers Association, said: “Todos has a diverse portfolio of initiatives, including his Tollovid as a natural immune support supplement, a robust R&D pipeline, COVID testing lab supplies, and life-saving diagnostic solutions. early detection of a variety of cancers. Unlike your typical biotech company, they make their money from consumer-marketed supplements. We look forward to sharing their stories with the B2i Digital investor community. I’m here. “
Gerald Commissiong, President and CEO of Todos Medical, said: “Tollovid is a brand that is perfectly timed for today’s challenges. With 10,000 Americans and more than 140 million people worldwide suffering from the long-term COVID-19, it is a global health crisis that severely impacts worker disability and worker productivity. , as the Federal Reserve recently admitted, is having a negative impact on gross domestic product.It is difficult to imagine a more pressing global health problem than dealing with COVID and Long COVID.Kingcarlx of We believe the #TolloUp marketing campaign and B2i Digital’s investor relations platform are important steps towards achieving our goals.”
About Todos Medical
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) develops life-saving diagnostic solutions for the early detection of a wide range of cancers.The company’s state-of-the-art patented Todos Biochemical Infrared Analysis (TBIA) is a proprietary cancer screening technology that uses peripheral blood analysis to examine the effects of cancer on the immune system by looking for biochemical changes in blood mononuclear cells and plasma. His two cancer screening tests, developed in-house by Todos, his TMB-1 and TMB-2, are CE marked in Europe. Todos recently acquired a US-based medical diagnostics company provista diagnosticsInc. will acquire the rights to a CLIA/CAP accredited lab based in Alpharetta, GA that is currently performing PCR COVID testing. long COVID painanalyse, and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. For more information on Provista, please visit: www.provistadx.com.
Todos is also developing blood tests for early detection of neurodegenerative diseases such as Alzheimer’s disease. The LymProliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBL) and monocytes to withstand exogenous mitotic stimuli that induce cell cycle entry. Certain diseases, particularly Alzheimer’s disease, are thought to be the result of disturbances in cellular machinery that cause abnormal cell cycle re-entry by neurons and subsequent apoptosis. LymPro is unique in using peripheral blood lymphocytes as a surrogate for neuronal function, suggesting a common connection between his PBL and neurons in the brain.
Todos will join forces with NLC Pharma in March 2022 to establish an Israel-based majority-owned joint venture, 3CL Pharma, Ltd, to develop diagnostic tests based on 3CL protease and 3CL targeting underlying reproductive functions. Combined all intellectual property in protease botanical and pharmaceutical inhibitor development. coronavirus mechanism. 3CL Pharma commercializes Tollovid™, a 3CL protease inhibitor immune support dietary supplement through the Todos brand. In the US, we are developing a dual-mechanism 3CL protease inhibitor and anti-cytokine therapeutic candidate, Tollovir™, while also developing TolloTest™ for 3CL protease diagnostics.
To purchase Tollovid, please visit: Amazon Also www.MyTollovid.com. For more information, see: https://www.todosmedical.com/.
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used in discussing anticipated clinical development programs and clinical trials. These forward-looking statements are based solely on management’s current expectations and are subject to significant risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. affected by Timing, costs and results of clinical trials and product development programs. difficulties or delays in obtaining regulatory approval or patent protection for product candidates; Competition from other biotech companies. our ability to obtain additional funding necessary to conduct our research, development and commercialization activities; In addition, actual results may differ materially from those set forth in the forward-looking statements, among other factors, including: Changes in technology and market requirements. Delays or impediments to initiation of clinical trials. changes in legislation; failure to develop and introduce new technologies, products, and applications in a timely manner; Lack of validation of our techniques as we progress further and lack of acceptance of our methods by the scientific community. Failure to retain or attract key employees with knowledge critical to product development. Unforeseen scientific difficulties that may arise in our process; Higher than expected final product cost. Loss of market share and pressure on prices due to competition. Any laboratory results that do not translate to equally good results in actual settings could cause actual results or performance to differ materially from those implied by such forward-looking statements. Todos Medical undertakes no obligation to publicly release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by Todos Medical. We do not owe. For more information on the risks and uncertainties affecting Todos Medical, please refer to reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos corporate contact:
Daniel Hirsch CFO
Press contact for Todos:
Vice President 973-975-7827